Lacosamide Tecnigen

Lacosamide, the active ingredient in Lacosamide Tecnigen, is an anti‑epileptic (sodium channel modulator) presented as an oral dosage form for oral use. It is indicated as adjunct therapy for partial‑onset seizures in patients with epilepsy. The medication works by enhancing the slow inactivation of voltage‑gated sodium channels, helping to stabilise neuronal membranes and reduce hyper‑excitability.

GNH USA supplies Lacosamide Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide.

Lacosamide is an anti‑epileptic drug that acts on neuronal sodium channels to control seizure activity.

- Partial‑onset seizures: reduces seizure frequency as adjunct therapy in epilepsy. - Focal seizures: used as add‑on treatment to improve seizure control. - Epilepsy (adjunct therapy): contributes to overall management of patients with focal onset seizures.

Lacosamide may cause a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate gastrointestinal upset. - Fatigue: increased tiredness or lack of energy. - Headache: mild to moderate pain in the head region.

Serious or Rare Side Effects: - Suicidal thoughts: emergence of depressive or suicidal ideation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmia: abnormal heart rhythm, including PR‑interval prolongation.

Before initiating therapy, clinicians should consider several safety aspects.

- Renal impairment: assess renal function and monitor for accumulation. - Hepatic impairment: use with caution and monitor liver enzymes. - Concomitant CNS depressants: observe for enhanced sedation or respiratory depression. - Pregnancy: safety data are limited; discuss potential risks with the prescriber. - Discontinuation: avoid abrupt cessation; taper under medical supervision. - Store at room temperature: keep in the original packaging, protect from moisture and heat.

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine): may lower lacosamide plasma levels. - Other sodium‑channel blockers (e.g., phenytoin): increased risk of CNS depression. - QT‑prolonging agents: potential additive effect on cardiac repolarisation.

Moderate Interactions (Monitor Closely): - Alcohol or CNS depressants: may enhance sedative effects. - Hormonal contraceptives: lacosamide may reduce contraceptive efficacy, requiring additional protection.